The global allogeneic cell therapy market size is expected to reach USD 1.72 billion by 2030, expanding at 27.40% CAGR from 2023 to 2030.Allogeneic cell therapy involves transferring cells from healthy donors to patients to treat chronic diseases such as cancer and cardiovascular diseases. The donor cells can be directly administered to genetically similar patients or added to a cell bank.
The therapies are typically produced in large batches from different donor tissues like bone marrow, and the manufacturing process is similar to that used for protein drugs and other large-scale derived materials. Allogeneic cell therapies offer several benefits over autologous therapies, including being less expensive and their availability as a scalable off-the-shelf product. As a result, the adoption of such therapies is increasing with several biotechnology companies conducting clinical trials treatment of various diseases.
There has been a significant increase in the number of allogeneic cell-based therapy clinical trials in recent years. According to the US National Institutes of Health, the number of mesenchymal stem cell (MSC) based clinical trials using cellular therapy has doubled over the last five years, with 1014 MSC-based clinical trials registered in the government database as either completed or in the process as of July 14th, 2021. This growth in clinical trials, combined with advancements in precision medicine and increased cell therapy production facilities is expected to drive market growth in the coming years.
The rising number of regulatory approvals for allogeneic cell-based therapies is expected to boost market growth over the forecast period. For instance, in October 2021, Enzyvant was granted FDA approval for its RETHYMIC, a single-dose regenerative tissue-based therapy for immunological reconstitution in pediatric patients with congenital athymia.
Moreover, in August 2022, Charles River Laboratories received approval from the European Medicines Agency (EMA) for its Memphis cell therapy manufacturing facility, which will enable the commercial production of allogeneic cell therapy. This approval is another significant milestone for the market, as it opens up new possibilities for treating various chronic diseases.
The COVID-19 pandemic had an unfavorable impact on the allogeneic stem cell therapy industry, causing a decline in research and development activities. This has disrupted various processes, including research, clinical trials, manufacturing, and logistics, ultimately affecting the quality of clinical evidence for cell and gene therapies. As a result, evaluating the treatment benefits and economic impacts of these therapies has become more challenging.
However, the pandemic has also raised awareness about the use of cell therapy as a potential treatment option for COVID-19. This increasing awareness is expected to have a positive impact on the market in the coming years. For instance, in May 2020, Lineage Cell Therapeutics received USD 5 million in emergency funding from the California Institute for Regenerative Medicine (CIRM) to develop a potential vaccine against SARS-CoV-2 using VAC, their allogeneic dendritic cell therapy.
The key players in the market are implementing several strategic initiatives to develop novel offerings. For instance, in February 2022, ONK Therapeutics entered into a collaboration with Intellia Therapeutics to develop five allogeneic NK cell therapies using Intellia's genome editing platform. This strategic partnership is expected to accelerate the development of novel therapies and contribute to high market growth.
This product will be delivered within 1-3 business days.
The therapies are typically produced in large batches from different donor tissues like bone marrow, and the manufacturing process is similar to that used for protein drugs and other large-scale derived materials. Allogeneic cell therapies offer several benefits over autologous therapies, including being less expensive and their availability as a scalable off-the-shelf product. As a result, the adoption of such therapies is increasing with several biotechnology companies conducting clinical trials treatment of various diseases.
There has been a significant increase in the number of allogeneic cell-based therapy clinical trials in recent years. According to the US National Institutes of Health, the number of mesenchymal stem cell (MSC) based clinical trials using cellular therapy has doubled over the last five years, with 1014 MSC-based clinical trials registered in the government database as either completed or in the process as of July 14th, 2021. This growth in clinical trials, combined with advancements in precision medicine and increased cell therapy production facilities is expected to drive market growth in the coming years.
The rising number of regulatory approvals for allogeneic cell-based therapies is expected to boost market growth over the forecast period. For instance, in October 2021, Enzyvant was granted FDA approval for its RETHYMIC, a single-dose regenerative tissue-based therapy for immunological reconstitution in pediatric patients with congenital athymia.
Moreover, in August 2022, Charles River Laboratories received approval from the European Medicines Agency (EMA) for its Memphis cell therapy manufacturing facility, which will enable the commercial production of allogeneic cell therapy. This approval is another significant milestone for the market, as it opens up new possibilities for treating various chronic diseases.
The COVID-19 pandemic had an unfavorable impact on the allogeneic stem cell therapy industry, causing a decline in research and development activities. This has disrupted various processes, including research, clinical trials, manufacturing, and logistics, ultimately affecting the quality of clinical evidence for cell and gene therapies. As a result, evaluating the treatment benefits and economic impacts of these therapies has become more challenging.
However, the pandemic has also raised awareness about the use of cell therapy as a potential treatment option for COVID-19. This increasing awareness is expected to have a positive impact on the market in the coming years. For instance, in May 2020, Lineage Cell Therapeutics received USD 5 million in emergency funding from the California Institute for Regenerative Medicine (CIRM) to develop a potential vaccine against SARS-CoV-2 using VAC, their allogeneic dendritic cell therapy.
The key players in the market are implementing several strategic initiatives to develop novel offerings. For instance, in February 2022, ONK Therapeutics entered into a collaboration with Intellia Therapeutics to develop five allogeneic NK cell therapies using Intellia's genome editing platform. This strategic partnership is expected to accelerate the development of novel therapies and contribute to high market growth.
Allogeneic Cell Therapy Market Report Highlights
- The stem cell therapies segment held the largest share of 77.00% in 2022. Allogeneic stem cell therapy is most frequently used to treat chronic diseases like blood cancers, leukemia, and lymphoma as well as specialized blood or autoimmune disorders
- By therapeutic area, the hematological disorders segments accounted for the largest share of 58.22% in the global allogeneic cell therapy industry in 2022. Since leading market players are implementing several strategic plans into action to create cutting-edge allogeneic cell therapies for hematological disease treatment
- North America held the largest market share of 80.42% in 2022. This can be attributed to the presence of the major global players in the market, and growing investments from public and private organizations for proteomic and life science research in the region
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Rising prevalence of chronic and infectious diseases
3.3.1.2. Increasing FDA approvals of allogeneic cell therapies
3.3.1.3. Increasing government funding for stem cell therapies
3.3.2. Market Restraint Analysis
3.3.2.1. High research costs and challenges with immune rejection
3.4. Industry Analysis Tools
3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.4.2. Porter's Five Forces Analysis
3.4.3. Penetration and Growth Prospect Mapping, 2022
3.5. Pipeline Analysis
3.6. COVID-19 Impact Analysis
Chapter 4. Allogeneic Cell Therapy Market: Therapy Type Business Analysis
4.1. Allogeneic Cell Therapy Market: Therapy Type Market Share Analysis
4.2. Allogeneic Cell Therapy Market Estimates & Forecast, By Therapy Type (USD Million)
4.3. Stem Cell Therapies
4.3.1. Global Stem Cell Therapies Market, 2018 - 2030 (USD Million)
4.3.2. Hematopoietic Stem Cell Therapies
4.3.2.1. Global Hematopoietic Stem Cell Therapies Market, 2018 - 2030 (USD Million)
4.3.3. Mesenchymal Stem Cell Therapies
4.3.3.1. Global Mesenchymal Stem Cell Therapies Market, 2018 - 2030 (USD Million)
4.4. Non-stem Cell Therapies
4.4.1. Global Non-stem Cell Therapies Market, 2018 - 2030 (USD Million)
4.4.2. Keratinocytes & Fibroblast-based Therapies
4.4.2.1. Global Keratinocytes & Fibroblast-based Therapies Market, 2018 - 2030 (USD Million)
4.4.3. Other Non-stem Cell Therapies
4.4.3.1. Global Other Non-stem Cell Therapies Market, 2018 - 2030 (USD Million)
Chapter 5. Allogeneic Cell Therapy Market: Therapeutic Area Business Analysis
5.1. Allogeneic Cell Therapy Market: Therapeutic Area Market Share Analysis
5.2. Allogeneic Cell Therapy Market Estimates & Forecast, By Therapeutic Area (USD Million)
5.3. Hematological Disorders
5.3.1. Global Haematological Disorders Market, 2018 - 2030 (USD Million)
5.4. Dermatological Disorders
5.4.1. Global Dermatological Disorders Market, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Global Other Therapeutic Areas Market, 2018 - 2030 (USD Million)
Chapter 6. Allogeneic Cell Therapy Market: Regional Business Analysis
6.1. Allogeneic Cell Therapy Market Share By Region, 2022 & 2030
6.2. North America
6.2.1. North America Allogeneic Cell Therapy Market, 2018 - 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Target Disease Prevalence
6.2.2.3. Competitive Scenario
6.2.2.4. Regulatory Framework
6.2.2.5. Reimbursement Scenario
6.2.2.6. U.S. Allogeneic Cell Therapy Market, 2018 - 2030 (USD Million)
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. Reimbursement Scenario
6.2.3.6. Canada Allogeneic Cell Therapy Market, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. Europe Allogeneic Cell Therapy Market, 2018 - 2030 (USD Million)
6.3.2. U.K.
6.3.2.1. Key Country Dynamics
6.3.2.2. Target Disease Prevalence
6.3.2.3. Competitive Scenario
6.3.2.4. Regulatory Framework
6.3.2.5. Reimbursement Scenario
6.3.2.6. U.K. Allogeneic Cell Therapy Market, 2018 - 2030 (USD Million)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. Reimbursement Scenario
6.3.3.6. Germany Allogeneic Cell Therapy Market, 2018 - 2030 (USD Million)
6.3.4. Switzerland
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. Reimbursement Scenario
6.3.4.6. Switzerland Allogeneic Cell Therapy Market, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Allogeneic Cell Therapy Market, 2018 - 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Competitive Scenario
6.4.2.4. Regulatory Framework
6.4.2.5. Reimbursement Scenario
6.4.2.6. Japan Allogeneic Cell Therapy Market, 2018 - 2030 (USD Million)
6.4.3. India
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Reimbursement Scenario
6.4.3.6. India Allogeneic Cell Therapy Market, 2018 - 2030 (USD Million)
6.4.4. South Korea
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. Reimbursement Scenario
6.4.4.6. South Korea Allogeneic Cell Therapy Market, 2018 - 2030 (USD Million)
6.5. Rest of the World
6.5.1. Rest of the World Allogeneic Cell Therapy Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Profiles/Listing
7.3.1. SSM Cardinal Glennon Children's Medical Center
7.3.1.1. Overview
7.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.1.3. Product Benchmarking
7.3.1.4. Strategic Initiatives
7.3.2. Cleveland Cord Blood Center
7.3.2.1. Overview
7.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.2.3. Product Benchmarking
7.3.2.4. Strategic Initiatives
7.3.3. Duke University School of Medicine
7.3.3.1. Overview
7.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.3.3. Product Benchmarking
7.3.3.4. Strategic Initiatives
7.3.4. New York Blood Center
7.3.4.1. Overview
7.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.4.3. Product Benchmarking
7.3.4.4. Strategic Initiatives
7.3.5. Clinimmune Labs, University of Colorado Cord Blood Bank
7.3.5.1. Overview
7.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.5.3. Product Benchmarking
7.3.5.4. Strategic Initiatives
7.3.6. MD Anderson Cord Blood Bank
7.3.6.1. Overview
7.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.6.3. Product Benchmarking
7.3.6.4. Strategic Initiatives
7.3.7. LifeSouth Community Blood Centers, Inc.
7.3.7.1. Overview
7.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.7.3. Product Benchmarking
7.3.7.4. Strategic Initiatives
7.3.8. Bloodworks Northwest
7.3.8.1. Overview
7.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.8.3. Product Benchmarking
7.3.8.4. Strategic Initiatives
7.3.9. JCR Pharmaceuticals Co., Ltd.
7.3.9.1. Overview
7.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.9.3. Product Benchmarking
7.3.9.4. Strategic Initiatives
7.3.10. Sumitomo Pharma Co., Ltd.
7.3.10.1. Overview
7.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.10.3. Product Benchmarking
7.3.10.4. Strategic Initiatives
7.3.11. Atara Biotherapeutics
7.3.11.1. Overview
7.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.11.3. Product Benchmarking
7.3.11.4. Strategic Initiatives
7.3.12. Mallinckrodt Pharmaceuticals
7.3.12.1. Overview
7.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.12.3. Product Benchmarking
7.3.12.4. Strategic Initiatives
7.3.13. Tego Science Inc.
7.3.13.1. Overview
7.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.13.3. Product Benchmarking
7.3.13.4. Strategic Initiatives
7.3.14. Takeda Pharmaceutical Company Limited.
7.3.14.1. Overview
7.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.14.3. Product Benchmarking
7.3.14.4. Strategic Initiatives
7.3.15. STEMPEUTICS RESEARCH PVT LTD.
7.3.15.1. Overview
7.3.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.15.3. Product Benchmarking
7.3.15.4. Strategic Initiatives
7.3.16. Biosolution Co., Ltd.
7.3.16.1. Overview
7.3.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.16.3. Product Benchmarking
7.3.16.4. Strategic Initiatives
7.3.17. MEDIPOST Co., Ltd.
7.3.17.1. Overview
7.3.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.17.3. Product Benchmarking
7.3.17.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global allogeneic cell therapy market, by therapy type, 2018 - 2030 (USD million)
Table 4 Global allogeneic cell therapy market, by therapeutic area, 2018 - 2030 (USD million)
Table 5 Global allogeneic cell therapy market, by region, 2018 - 2030 (USD million)
Table 6 North America allogeneic cell therapy market, by country, 2018 - 2030 (USD million)
Table 7 North America allogeneic cell therapy market, by therapy type, 2018 - 2030 (USD million)
Table 8 North America allogeneic cell therapy market, by therapeutic area, 2018 - 2030 (USD million)
Table 9 U.S. allogeneic cell therapy market, by therapy type, 2018 - 2030 (USD million)
Table 10 U.S. allogeneic cell therapy market, by therapeutic area, 2018 - 2030 (USD million)
Table 11 Canada allogeneic cell therapy market, by therapy type, 2018 - 2030 (USD million)
Table 12 Canada allogeneic cell therapy market, by therapeutic area, 2018 - 2030 (USD million)
Table 13 Europe allogeneic cell therapy market, by country, 2018 - 2030 (USD million)
Table 14 Europe allogeneic cell therapy market, by therapy type, 2018 - 2030 (USD million)
Table 15 Europe allogeneic cell therapy market, by therapeutic area, 2018 - 2030 (USD million)
Table 16 U.K. allogeneic cell therapy market, by therapy type, 2018 - 2030 (USD million)
Table 17 U.K. allogeneic cell therapy market, by therapeutic area, 2018 - 2030 (USD million)
Table 18 Germany allogeneic cell therapy market, by therapy type, 2018 - 2030 (USD million)
Table 19 Germany allogeneic cell therapy market, by therapeutic area, 2018 - 2030 (USD million)
Table 20 Switzerland allogeneic cell therapy market, by therapy type, 2018 - 2030 (USD million)
Table 21 Switzerland allogeneic cell therapy market, by therapeutic area, 2018 - 2030 (USD million)
Table 22 Asia Pacific allogeneic cell therapy market, by country, 2018 - 2030 (USD million)
Table 23 Asia Pacific allogeneic cell therapy market, by therapy type, 2018 - 2030 (USD million)
Table 24 Asia Pacific allogeneic cell therapy market, by therapeutic area, 2018 - 2030 (USD million)
Table 25 Japan allogeneic cell therapy market, by therapy type, 2018 - 2030 (USD million)
Table 26 Japan allogeneic cell therapy market, by therapeutic area, 2018 - 2030 (USD million)
Table 27 India allogeneic cell therapy market, by therapy type, 2018 - 2030 (USD million)
Table 28 India allogeneic cell therapy market, by therapeutic area, 2018 - 2030 (USD million)
Table 29 South Korea allogeneic cell therapy market, by therapy type, 2018 - 2030 (USD million)
Table 30 South Korea allogeneic cell therapy market, by therapeutic area, 2018 - 2030 (USD million)
Table 31 Rest of the world allogeneic cell therapy market, by therapy type, 2018 - 2030 (USD million)
Table 32 Rest of the world allogeneic cell therapy market, by therapeutic area, 2018 - 2030 (USD million)
Table 33 Participant's overview
Table 34 Financial performance
Table 35 Key companies undergoing expansions
Table 36 Key companies undergoing acquisitions
Table 37 Key companies undergoing collaborations
Table 38 Key companies launching new products/services
Table 39 Key companies undertaking other strategies
List of Figures
Fig. 1 Allogeneic cell therapy market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market Snapshot
Fig. 10 Segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Parent market outlook
Fig. 13 Related/ancillary market outlook
Fig. 14 Small-scale bioreactors - Industry value chain analysis
Fig. 15 Allogeneic cell therapy market driver analysis
Fig. 16 Allogeneic cell therapy market restraint analysis
Fig. 17 Allogeneic cell therapy market: Porter's analysis
Fig. 18 Allogeneic cell therapy market: PESTLE analysis
Fig. 19 Allogeneic cell therapy market: Therapy type outlook and key takeaways
Fig. 20 Allogeneic cell therapy market: Therapy type market share analysis, 2022 - 2030
Fig. 21 Global stem cell therapies market, 2018 - 2030 (USD million)
Fig. 22 Global hematopoietic stem cell therapies market, 2018 - 2030 (USD million)
Fig. 23 Global mesenchymal stem cell therapies market, 2018 - 2030 (USD million)
Fig. 24 Global non-stem cell therapies market, 2018 - 2030 (USD million)
Fig. 25 Global keratinocytes & fibroblast-based therapies market, 2018 - 2030 (USD million)
Fig. 26 Global other therapy types market, 2018 - 2030 (USD million)
Fig. 27 Allogeneic cell therapy market: Therapeutic area outlook and key takeaways
Fig. 28 Allogeneic cell therapy market: Therapeutic area market share analysis, 2022 - 2030
Fig. 29 Global hematological disorders market, 2018 - 2030 (USD million)
Fig. 30 Global dermatological disorders market, 2018 - 2030 (USD million)
Fig. 31 Global others therapeutic areas market, 2018 - 2030 (USD million)
Fig. 32 Regional marketplace: Key takeaways
Fig. 33 Regional marketplace: Key takeaways
Fig. 34 North America allogeneic cell therapy market estimates and forecast, 2018 - 2030 (USD million)
Fig. 35 U.S. key country dynamics
Fig. 36 U.S. allogeneic cell therapy market estimates and forecast, 2018 - 2030 (USD million)
Fig. 37 Canada key country dynamics
Fig. 38 Canada allogeneic cell therapy market, 2018 - 2030 (USD million)
Fig. 39 Europe allogeneic cell therapy market estimates and forecast, 2018 - 2030 (USD million)
Fig. 40 U.K. key country dynamics
Fig. 41 U.K. allogeneic cell therapy market estimates and forecast, 2018 - 2030 (USD million)
Fig. 42 Germany key country dynamics
Fig. 43 Germany allogeneic cell therapy market estimates and forecast, 2018 - 2030 (USD million)
Fig. 44 Switzerland key country dynamics
Fig. 45 Switzerland allogeneic cell therapy market estimates and forecast, 2018 - 2030 (USD million)
Fig. 46 Asia-Pacific allogeneic cell therapy market estimates and forecast, 2018 - 2030 (USD million)
Fig. 47 Japan key country dynamics
Fig. 48 Japan allogeneic cell therapy market estimates and forecast, 2018 - 2030 (USD million)
Fig. 49 India key country dynamics
Fig. 50 India allogeneic cell therapy market estimates and forecast, 2018 - 2030 (USD million)
Fig. 51 South Korea key country dynamics
Fig. 52 South Korea allogeneic cell therapy market estimates and forecast, 2018 - 2030 (USD million)
Fig. 53 Rest of the world allogeneic cell therapy market estimates and forecast, 2018 - 2030 (USD million)
Fig. 54 Key company categorization
Fig. 55 Company market positioning
Fig. 56 Market participant categorization
Fig. 57 Strategy framework
Companies Mentioned
- SSM Cardinal Glennon Children's Medical Center
- Cleveland Cord Blood Center
- Duke University School of Medicine
- New York Blood Center
- Clinimmune Labs, University of Colorado Cord Blood Bank
- MD Anderson Cord Blood Bank
- LifeSouth Community Blood Centers, Inc.
- Bloodworks Northwest
- JCR Pharmaceuticals Co., Ltd.
- Sumitomo Pharma Co., Ltd.
- Atara Biotherapeutics
- Mallinckrodt Pharmaceuticals
- Tego Science Inc.
- Takeda Pharmaceutical Company Limited.
- STEMPEUTICS RESEARCH PVT LTD.
- Biosolution Co., Ltd.
- MEDIPOST Co., Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | March 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 255.6 Million |
| Forecasted Market Value ( USD | $ 1720 Million |
| Compound Annual Growth Rate | 27.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
